FDMT - 4D Molecular Therapeutics Short-Term Debt to Capital

The absence of market-based pricing and a reliance on scientific publications define the current status of 4D Molecular Therapeutics (FDMT), where the indicator stands at 0.03. High expenditures in the absence of sales create a severe dependence on external financing. This price chart reflects the dynamics of the company, which possesses significant scientific potential and develops advanced gene therapy methods using an IT platform to optimize DNA vectors.

For the grant-dependent biotech startup 4D Molecular Therapeutics (FDMT), this indicator assesses short-term financial stability through the lens of debt load. The metric compares liabilities maturing within one year against total shareholders' equity. The trend of the short-term leverage ratio allows for tracking liquidity risk until 4D Molecular Therapeutics (FDMT) reaches break-even. A decrease in these values confirms the effectiveness of external financing and the minimization of pressure on assets.